Gastroesophageal Cancer Treatment: Practice Advances
The ESOPEC trial established perioperative FLOT as superior to CROSS-based chemoradiation for resectable esophageal adenocarcinoma in fit surgical candidates; NCCN guidelines now reflect this.
This review summarizes recent advances in the management of gastroesophageal cancers, emphasizing the shift toward perioperative FLOT chemotherapy over chemoradiation for resectable esophageal adenocarcinoma, the incorporation of HER2-targeted and claudin 18.2‑directed therapies in metastatic disease, and evolving biomarker‑driven strategies, including PD‑L1 testing in perioperative settings.
These developments refine standard‑of‑care decisions, improve patient selection for targeted and immune‑based treatments, and lay the groundwork for integrating emerging agents into routine practice.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells